Member Info for BuenaVista

Sorry, for that 5 minute time slot. Now about 2.165m

Just before or around 12:10.

May be the volume for that minute, but even so...

https://uk.investing.com/equities/avacta-group-plc-chart

US site thinks UK stocks priced in pounds. A 47p hold makes (marginally) more sense.

.

Thanks for the clarifications

For at least the second time Avacta fails to win a Best Fruit competition.

What is the proof that that was a worked buy and not a worked sell?

If that was a worked buy, who's been selling shares for that and all the shares retail investors have been buying? Timeframe? Volumes?

Treasureisland, your ignorance is only surpassed by your stupidity.

It has been working fine Safebreaker. The live streaming prices work when I'm not logged in until my laptop has a Firefox upgrade, at which time I have to log in and rest the live streaming prices (cookies or something wiped out). That is not the problem. The problem is with the new chart interface on the 'Charts & Performance' tab. It is a transient problem because - probably due to the tsunami of complaints they'll be getting - they remove it after a few minutes and revert to the 'old', working, interface. The 'new' one is an interactive, manipulable interface like on Yahoo! Finance except it don't work. Really unprofessional of HL. They should have tested it thoroughly on a development (inhouse) server before putting it on their publicly-accessible server.

Are you looking at the old interface, which is back for me, or the new one which appeared briefly today and Tuesday (at least) around lunchtime?

Is this working for anyone? It made a brief appearance on Tuesday and again just now.

For me, the live prices revert to 'delayed by at least 15 minutes' and the RSI graph is blank/nonexistent. That's for starters but it's enough to make it useless.

I gave a bad review to the survey and today complained about how rubbish it is. Anyone else complaining?

@john0011, if you can say who the top 3 institutions are:

"54% of the business is held by the top 3 shareholders", "A look at the shareholders of Avacta Group Plc (LON:AVCT) can tell us which group is most powerful. The group holding the most number of shares in the company, around 83% to be precise, is institutions."

then you will understand who holds the majority of the Avacta shares and how reliable Simply Wall St.

Take your time.

Live trades: https://www.investing.com/equities/avacta-group-plc-chart

Given this from the Pipeline page: "The AVA7100 program is in the preclinical setting and is anticipated to have candidate selection in 2H 2025 with a potential IND in 2H 2026" I would say that they must have decided on the warhead by now, but not necessarily the full structure (self-immolative linker, if any, and Affimer capping group). I think it will be like AVA6103's announcement last year - data from a selection of AVA7100 candidates.

Also, they have a lot of AVA6103 data ready for the IND submission in Q4 2025/Q1 2026 that they can, and I think will, present at the conference - if not then, when?

But what could be really interesting is if they have extended the pipeline and present on something that we currently know nothing about.

63/64

RELEASE DATE FOR REGULAR, CLINICAL TRIAL, AND LATE-BREAKING ABSTRACTS

Regular, clinical trial, and late-breaking abstract titles and authors (no data) will be available on the AACR website on Monday, October 13, 2025, at 12 p.m. ET.

Regular abstracts (as outlined above) that are selected for presentation during the conference (poster or oral) will be released as a freely available supplement in the AACR journal Molecular Cancer Therapeutics and will be available in the conference app at 12 p.m. ET on Wednesday, October 22, 2025, with the exception of abstracts selected for inclusion in the AACR press program.

Clinical trial abstracts and late-breaking abstracts (as outlined above) that are selected for presentation during the conference (poster or oral) will be released in the conference app at 12 p.m. ET on Wednesday, October 22, 2025, with the exception of abstracts selected for inclusion in the AACR press program.

Abstracts selected for inclusion in the AACR press program (regular, clinical trial, or late-breaking) will be released in the conference app at the date and time that their press embargo lifts.

Abstracts will not be available before these dates.

- - - - -

So, going by last year, we can possibly expect an outline RNS after hours on Monday 13th or 7am the next day, and an RNS with the abstract(s) at the same times on the 22nd/23rd - unless in th eunlikely event that we have something in the AACR press program.

Last year's RNS was 10 October for 24 October: https://avacta.com/avacta-to-unveil-pipeline-expansion-and-novel-next-generational-targeted-cancer-therapy-programs-at-2024-eortc-nci-aacr-symposium/

Very tight spread. Just been quoted 63.6532 to sell 20,000 and 10,000 shares. Looks like 63/64 is going to fall.

@Bella, that may be a good strategy for getting started but it would be hopeless longterm as Avacta is just not big enough and couldn't grow quickly enough to take on multiple trials for multiple candidate drugs in multiple indications.